Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.06), Bloomberg Earnings reports. During the same period in the previous year, the firm earned ($0.62) earnings per share.

In other Sunesis Pharmaceuticals news, Director Dayton Misfeldt purchased 400,000 shares of the stock in a transaction on Friday, October 27th. The stock was bought at an average cost of $2.00 per share, for a total transaction of $800,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 10.21% of the stock is owned by corporate insiders.

A hedge fund recently raised its stake in Sunesis Pharmaceuticals stock. Vanguard Group Inc. grew its holdings in Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) by 4.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 605,759 shares of the biopharmaceutical company’s stock after acquiring an additional 23,819 shares during the quarter. Vanguard Group Inc. owned 2.58% of Sunesis Pharmaceuticals worth $1,635,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 57.56% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Sunesis Pharmaceuticals, Inc. (SNSS) Announces Earnings Results, Misses Estimates By $0.06 EPS” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/sunesis-pharmaceuticals-inc-snss-announces-earnings-results-misses-estimates-by-0-06-eps/1674021.html.

A number of brokerages have commented on SNSS. Zacks Investment Research upgraded Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research report on Thursday, August 24th. Cowen and Company restated a “hold” rating on shares of Sunesis Pharmaceuticals in a research report on Thursday. Cantor Fitzgerald restated a “hold” rating and set a $3.00 price objective on shares of Sunesis Pharmaceuticals in a research report on Wednesday, September 27th. Finally, ValuEngine lowered Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.

About Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.